
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$35.17
+US$0.10 · +0.29%
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
一般交易時段
US$35.17
+US$0.10 · +0.29%
盤中時間採用ET。市場資料可能有所延遲。
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
日內區間
目前US$35.17
52週區間
目前US$35.17
盤中時間採用ET。市場資料可能有所延遲。
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
日內區間
目前US$35.17
52週區間
目前US$35.17
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.03億 USD | 8667.24萬 USD | 6498.98萬 USD | 4584.28萬 USD | 2414.39萬 USD |
| 銷貨成本 | 1018.28萬 USD | 813.99萬 USD | 785.27萬 USD | 636.09萬 USD | 231.12萬 USD |
| 毛利 | 9293.51萬 USD | 7853.25萬 USD | 5713.72萬 USD | 3948.2萬 USD | 2183.27萬 USD |
| 研究與開發 | 507.25萬 USD | 570.34萬 USD | 413.24萬 USD | 336.7萬 USD | 55.87萬 USD |
| 銷售、一般及管理費用 | 7871.7萬 USD | 7655.99萬 USD | 5699.48萬 USD | 4597.63萬 USD | 2805.32萬 USD |
| 營業費用 | 8378.95萬 USD | 8524.8萬 USD | 6135.23萬 USD | 5199.92萬 USD | 2920.89萬 USD |
| 利息收入 | 3672 USD | 2.2萬 USD | — | 28.47萬 USD | — |
| 利息支出 | 675.98萬 USD | 312.84萬 USD | 47.58萬 USD | 28.47萬 USD | 711 USD |
| 折舊和攤銷 | 2855.8萬 USD | 492.32萬 USD | 367.5萬 USD | 237.11萬 USD | 59.7萬 USD |
| 營業利益 | 914.57萬 USD | −671.55萬 USD | −421.52萬 USD | −1251.72萬 USD | −737.62萬 USD |
| 淨利 | −3756.26萬 USD | −966.45萬 USD | −430.32萬 USD | −793.75萬 USD | −792.19萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$35.00
下跌空間 0.48%評級樣本有限,僅3項
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息即將實施 | 2027年7月29日 | US$33.00Irregular | — | — |
除息 2027年7月29日
US$33.00
Irregular
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。